Noor Wortelboer

Rotterdam, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Overall Survival With First-Line vs Second-Line CDK4/6 Inhibitor Use in Advanced Breast Cancer: A Randomized Clinical Trial.

Overall Survival With First-Line vs Second-Line CDK4/6 Inhibitor Use in Advanced Breast Cancer: A Randomized Clinical Trial.

Journal: JAMA oncology

Published: February 19, 2026

Cognitive function during endocrine treatment with or without cyclin-dependent kinase 4/6 inhibitors for advanced breast cancer.

Cognitive function during endocrine treatment with or without cyclin-dependent kinase 4/6 inhibitors for advanced breast cancer.

Journal: Cancer

Published: July 31, 2025

Author Correction: Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer.

Author Correction: Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer.

Journal: Nature

Published: July 22, 2025

Health-related quality of life with first- vs second-line CDK4/6 inhibitor use in advanced breast cancer: results from the SONIA trial.

Health-related quality of life with first- vs second-line CDK4/6 inhibitor use in advanced breast cancer: results from the SONIA trial.

Journal: Journal of the National Cancer Institute

Published: June 20, 2025

Health-related quality of life with first- vs second-line CDK4/6 inhibitor use in advanced breast cancer: results from the SONIA trial.

Health-related quality of life with first- vs second-line CDK4/6 inhibitor use in advanced breast cancer: results from the SONIA trial.

Journal: Journal of the National Cancer Institute

Published: June 20, 2025

Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trial.

Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trial.

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 12, 2025

Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer: circulating tumor DNA analysis of a randomized phase 3 trial.

Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer: circulating tumor DNA analysis of a randomized phase 3 trial.

Journal: Nature medicine

Published: February 24, 2025

Palbociclib exposure in relation to efficacy and toxicity in patients with advanced breast cancer.

Palbociclib exposure in relation to efficacy and toxicity in patients with advanced breast cancer.

Journal: ESMO open

Published: October 28, 2024

Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer.

Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer.

Journal: Nature

Published: January 09, 2024

Showing 1-9 of 9

Last Updated: 09/26/2026